2016-12-14 |
14 |
Status Report |
and/or (c).
Amgen also owns U.S. Patent No. 6,011,068, which is listed in the Orange Book listing…undergo parathyroidectomy. U.S.
Patent No. 9,375,405 (the “’405 patent”) is listed in Approved Drug Products…‘405 patent invalid.
2. A judgment that no asserted claim of the ‘405 patent is infringed…Substance of the Actions
These are Hatch-Waxman patent infringement actions relating to cinacalcet hydrochloride…United States prior to the expiration of the ’405 patent. By letter dated August 5,
2016, Aurobindo notified |
External link to document |
2018-03-23 |
348 |
Consent Judgment |
admitted that Amgen’s United States Patent Number 9,375,405
(the “Amgen Patent”) is enforceable and valid.
…
Settlement Agreement, would infringe the Amgen Patent.
5. Defendants, including any of its successors…successors and assigns, are enjoined under the
’405 patent, and under any extensions and/or additional periods…
or becomes entitled, from infringing the Amgen Patent, on its own part or through any Afflliate,
by making…22 September 2016
1:16-cv-00853
830 Patent
None
District Court, D. Delaware
|
External link to document |
2018-04-19 |
357 |
Memorandum Opinion |
Defendants infringed United States
Patent No. 9,375,405 (“the ’405 patent”) titled “Rapid Dissolution Formulation… 1. The ’405 Patent
The ’405 patent issued from U.S. Patent Application No. 12/942,…OPINION
This is a consolidated case for patent infringement brought by Plaintiff Amgen Inc.
(…construed the meaning of the Markush groups in the ’405 patent; and (ii) Zydus’ Motion in
Limine to preclude …case will be decided based on claim 1 of the ’405 patent, which states:
(1) A pharmaceutical |
External link to document |
2018-07-27 |
375 |
Opinion |
2 through 24 as obvious “over Van Wagenen (US 6,211,244 B1) as evidenced by
Kajiyama et al. (US 6,656,492…consolidated patent infringement action arising under the Drug Price
Competition and Patent Term Restoration…Hatch-Waxman Act. United States Patent No. 9,375,405 (the “’405 patent”) is assigned to
Plaintiff Amgen…BACKGROUND
A. The ’405 Patent
The ’405 patent, entitled “Rapid Dissolution Formulation… was issued by the United States Patent and Trademark Office (“Patent Office”) on
June 28, 2016. (D.I |
External link to document |
2018-07-27 |
376 |
Order |
-12, and 14-18 of United States Patent No. 9,375,405 ('the '405 patent"); 2. Piramal does not infringe…20 of the '405 patent; and 4. Zydus does not infringe claims 18 and 20 of the 405 patent; but 5. Zydus … it, which are claims 1-6 and 8- 20 of the '405 patent; 3. Watson does not infringe any of the claims …infringe claims 1-4, 6, 8-9, 15-17, and 19 of the 405 patent, to the extent each claim is found valid and enforceable…22 September 2016
1:16-cv-00853
830 Patent
None
District Court, D. Delaware
|
External link to document |